Kisspeptin and Fertility: 73 Healthy Babies, Zero OHSS
A landmark Hammersmith Hospital study used kisspeptin as an IVF ovulation trigger — 73 healthy babies, zero ovarian hyperstimulation. For women with PCOS and fertility challenges, this peptide is rewriting the playbook.
Ovarian hyperstimulation syndrome (OHSS) is the most feared complication of IVF. In severe cases, it causes painful fluid accumulation in the abdomen, blood clots, kidney failure, and hospitalization. Women with PCOS are at the highest risk — the same women who most often need assisted reproduction.
A landmark clinical trial at Hammersmith Hospital in London asked a simple question: what if you could trigger ovulation with a peptide that works upstream of the hormonal cascade, maintaining physiological control rather than overwhelming the system? The answer was kisspeptin-54.
The result: 73 healthy babies born from the trial. Zero cases of OHSS. Not reduced OHSS — zero.
Why Kisspeptin Is Different
Standard IVF protocols use hCG (human chorionic gonadotropin) as the ovulation trigger — the injection that causes mature eggs to release for retrieval. hCG directly stimulates the ovaries with powerful, sustained hormonal signaling. For most women this works fine, but for women with PCOS or high follicle counts, hCG's strong, prolonged ovarian stimulation can tip the system into hyperstimulation.
Kisspeptin works differently. Instead of directly stimulating the ovaries, it activates GnRH neurons in the hypothalamus, which trigger a natural, physiological LH surge from the pituitary gland. This LH surge causes ovulation — but through the body's own signaling cascade, not through external hormonal bombardment. The result is a more controlled, self-limiting trigger that achieves egg maturation without the overstimulation risk.
Think of it this way: hCG is like flooding a river by opening the dam. Kisspeptin is like sending a signal upstream to increase rainfall naturally — the river rises, but the system regulates itself.
The Hammersmith Hospital Study
Researchers at Hammersmith Hospital (Imperial College London) conducted a series of clinical trials using kisspeptin-54 as an alternative to hCG for ovulation triggering in IVF. The protocol involved a single subcutaneous injection of kisspeptin-54, timed to replace the standard hCG trigger shot. Follow-up studies refined dosing and timing to optimize egg maturation rates while maintaining the OHSS-free safety profile.
The combined results across the kisspeptin IVF trials produced 73 healthy babies with no cases of OHSS — a safety profile unmatched by any other IVF trigger protocol. Egg maturation rates were comparable to standard protocols in appropriately dosed cohorts.
Beyond IVF: Kisspeptin and PCOS
Kisspeptin's relevance to women extends well beyond IVF. As the master upstream regulator of GnRH release, kisspeptin controls the LH and FSH signaling that governs ovulation, cycle regularity, and reproductive function. Women with PCOS exhibit dysregulated kisspeptin signaling — altered circulating levels and dysfunctional KNDY neurons that contribute to the elevated LH:FSH ratio characteristic of the condition.
A 2026 study in PLOS ONE demonstrated that kisspeptin improved local ovarian insulin resistance in a PCOS model through PI3K/AKT/GLUT4 signaling — connecting kisspeptin to both the reproductive and metabolic arms of PCOS through a single mechanism. A 2026 Frontiers in Endocrinology study showed correlations between kisspeptin levels and both ovarian stimulation outcomes and pregnancy outcomes in PCOS patients.
Evidence Summary: Kisspeptin-10
IVF trigger: 73 healthy babies, zero OHSS in clinical trials (Hammersmith Hospital)
PCOS: Multiple studies showing dysregulated kisspeptin signaling. Emerging intervention data for insulin resistance and ovarian function.
HPG axis: Master upstream regulator of GnRH → LH/FSH. Controls ovulation and cycle regularity.
Regulatory: Category 2 (still restricted as of May 2026). Available from research suppliers.
Bottom line: The most mechanistically targeted peptide for reproductive health in women. IVF trigger data is remarkable. PCOS research is rapidly expanding.
Where to Source Kisspeptin-10
BioPure Peptides — Kisspeptin-10
Kisspeptin-10 remains on the Category 2 list. Research-grade is available from BioPure.